Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Revenue: 2014-2025

Historic Revenue for ImmunityBio (IBRX) over the last 12 years, with Sep 2025 value amounting to $32.1 million.

  • ImmunityBio's Revenue rose 425.07% to $32.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.6 million, marking a year-over-year increase of 1025.95%. This contributed to the annual value of $14.7 million for FY2024, which is 2270.58% up from last year.
  • As of Q3 2025, ImmunityBio's Revenue stood at $32.1 million, which was up 21.33% from $26.4 million recorded in Q2 2025.
  • ImmunityBio's Revenue's 5-year high stood at $32.1 million during Q3 2025, with a 5-year trough of $14,000 in Q1 2022.
  • In the last 3 years, ImmunityBio's Revenue had a median value of $1.0 million in 2024 and averaged $8.2 million.
  • As far as peak fluctuations go, ImmunityBio's Revenue plummeted by 89.93% in 2022, and later surged by 41,192.50% in 2025.
  • ImmunityBio's Revenue (Quarterly) stood at $390,000 in 2021, then crashed by 81.28% to $73,000 in 2022, then soared by 90.41% to $139,000 in 2023, then skyrocketed by 5,333.09% to $7.6 million in 2024, then skyrocketed by 425.07% to $32.1 million in 2025.
  • Its last three reported values are $32.1 million in Q3 2025, $26.4 million for Q2 2025, and $16.5 million during Q1 2025.